S&P 500   3,798.12 (+0.19%)
DOW   30,400.19 (+0.28%)
QQQ   283.45 (+0.47%)
AAPL   147.13 (+0.70%)
MSFT   250.40 (+0.61%)
META   140.04 (-0.17%)
GOOGL   101.82 (+0.18%)
AMZN   121.62 (+0.44%)
TSLA   241.62 (-3.14%)
NVDA   132.97 (+0.99%)
NIO   16.13 (-3.59%)
BABA   84.79 (+0.81%)
AMD   68.53 (+0.93%)
T   15.98 (-0.68%)
MU   55.03 (+1.98%)
CGC   3.05 (-2.87%)
F   12.53 (+1.38%)
GE   68.07 (+0.78%)
DIS   100.93 (-0.50%)
AMC   7.39 (-5.62%)
PYPL   94.45 (+1.79%)
PFE   44.26 (-0.45%)
NFLX   238.17 (-1.07%)
S&P 500   3,798.12 (+0.19%)
DOW   30,400.19 (+0.28%)
QQQ   283.45 (+0.47%)
AAPL   147.13 (+0.70%)
MSFT   250.40 (+0.61%)
META   140.04 (-0.17%)
GOOGL   101.82 (+0.18%)
AMZN   121.62 (+0.44%)
TSLA   241.62 (-3.14%)
NVDA   132.97 (+0.99%)
NIO   16.13 (-3.59%)
BABA   84.79 (+0.81%)
AMD   68.53 (+0.93%)
T   15.98 (-0.68%)
MU   55.03 (+1.98%)
CGC   3.05 (-2.87%)
F   12.53 (+1.38%)
GE   68.07 (+0.78%)
DIS   100.93 (-0.50%)
AMC   7.39 (-5.62%)
PYPL   94.45 (+1.79%)
PFE   44.26 (-0.45%)
NFLX   238.17 (-1.07%)
S&P 500   3,798.12 (+0.19%)
DOW   30,400.19 (+0.28%)
QQQ   283.45 (+0.47%)
AAPL   147.13 (+0.70%)
MSFT   250.40 (+0.61%)
META   140.04 (-0.17%)
GOOGL   101.82 (+0.18%)
AMZN   121.62 (+0.44%)
TSLA   241.62 (-3.14%)
NVDA   132.97 (+0.99%)
NIO   16.13 (-3.59%)
BABA   84.79 (+0.81%)
AMD   68.53 (+0.93%)
T   15.98 (-0.68%)
MU   55.03 (+1.98%)
CGC   3.05 (-2.87%)
F   12.53 (+1.38%)
GE   68.07 (+0.78%)
DIS   100.93 (-0.50%)
AMC   7.39 (-5.62%)
PYPL   94.45 (+1.79%)
PFE   44.26 (-0.45%)
NFLX   238.17 (-1.07%)
S&P 500   3,798.12 (+0.19%)
DOW   30,400.19 (+0.28%)
QQQ   283.45 (+0.47%)
AAPL   147.13 (+0.70%)
MSFT   250.40 (+0.61%)
META   140.04 (-0.17%)
GOOGL   101.82 (+0.18%)
AMZN   121.62 (+0.44%)
TSLA   241.62 (-3.14%)
NVDA   132.97 (+0.99%)
NIO   16.13 (-3.59%)
BABA   84.79 (+0.81%)
AMD   68.53 (+0.93%)
T   15.98 (-0.68%)
MU   55.03 (+1.98%)
CGC   3.05 (-2.87%)
F   12.53 (+1.38%)
GE   68.07 (+0.78%)
DIS   100.93 (-0.50%)
AMC   7.39 (-5.62%)
PYPL   94.45 (+1.79%)
PFE   44.26 (-0.45%)
NFLX   238.17 (-1.07%)
NASDAQ:ISEE

IVERIC bio - ISEE Stock Forecast, Price & News

$20.80
+1.02 (+5.16%)
(As of 10/5/2022 03:22 PM ET)
Add
Compare
Today's Range
$19.61
▼
$21.33
50-Day Range
$9.44
▼
$19.78
52-Week Range
$8.85
▼
$20.99
Volume
202,099 shs
Average Volume
13.65 million shs
Market Capitalization
$2.46 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.00

IVERIC bio MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
25.0% Upside
$26.00 Price Target
Short Interest
Bearish
7.86% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.10mentions of IVERIC bio in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$211,373 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.49) to ($1.53) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.82 out of 5 stars

Medical Sector

507th out of 1,072 stocks

Pharmaceutical Preparations Industry

235th out of 534 stocks

See Top Rated MarketRank™ Stocks Here
ISEE stock logo

About IVERIC bio (NASDAQ:ISEE) Stock

IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.

Receive ISEE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter.

ISEE Stock News Headlines

October 5, 2022 | benzinga.com
IVERIC bio Whale Trades For October 05
September 27, 2022 | finance.yahoo.com
Iveric Bio to Present Top-line Results for Avacincaptad Pegol from Phase 3 GATHER2 Clinical Trial in Geographic Atrophy at AAO 2022 Annual Meeting
September 8, 2022 | finance.yahoo.com
Why Iveric Bio Stock Is Skyrocketing This Week
September 7, 2022 | markets.businessinsider.com
Analyst Ratings for IVERIC bio
September 7, 2022 | finance.yahoo.com
Iveric Bio to Present at Upcoming Investor Conferences
September 6, 2022 | seekingalpha.com
Hot Stocks: Trump SPAC DWAC drops; FRO rallies on upgrade; ISEE jumps on clinical data; SMG sets new 52-week low
September 6, 2022 | nasdaq.com
Iveric Bio's Gather 2 Phase 3 Trial Meets Primary Endpoint For Zimura
September 6, 2022 | seekingalpha.com
Iveric stock soars 41% as eye disorder drug Zimura meets main goal in phase 3 trial
September 6, 2022 | markets.businessinsider.com
Iveric Bio Shares Shoot Higher Following Positive Top-line Data From Late-Stage Geographic Atrophy Study
September 6, 2022 | finance.yahoo.com
Iveric Bio Announces Positive Topline Data from Zimura® GATHER2 Phase 3 Clinical Trial in Geographic Atrophy
September 3, 2022 | nasdaq.com
Noteworthy Friday Option Activity: FIVE, ISEE, KEX
September 2, 2022 | benzinga.com
This Is What Whales Are Betting On IVERIC bio
August 10, 2022 | finance.yahoo.com
Iveric Bio to Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
August 2, 2022 | markets.businessinsider.com
What 5 Analyst Ratings Have To Say About IVERIC bio
July 26, 2022 | seekingalpha.com
IVERIC bio, Inc. (ISEE) CEO Glenn Sblendorio on Q2 2022 Results - Earnings Call Transcript
July 26, 2022 | finance.yahoo.com
IVERIC bio Shares Jump On Debt Financing To Fund Zimura Launch
July 26, 2022 | finance.yahoo.com
IVERIC bio, Inc. (ISEE) Q2 2022 Earnings Call Transcript
July 26, 2022 | finance.yahoo.com
Iveric Bio Reports Second Quarter 2022 Operational Highlights and Financial Results
July 21, 2022 | finance.yahoo.com
Iveric Bio to Report Second Quarter 2022 Financial Results and Host Conference Call on Tuesday, July 26, 2022
July 21, 2022 | markets.businessinsider.com
Short Volatility Alert: IVERIC bio, Inc.
July 19, 2022 | seekingalpha.com
Iveric Bio, NGM gain as Apellis wins priority review for GA candidate
July 19, 2022 | nasdaq.com
First Week of March 2023 Options Trading For IVERIC bio
July 16, 2022 | finance.yahoo.com
Iveric Bio Announces Post-Hoc Analysis from GATHER1 Clinical Trial of Zimura® at American Society of Retina Specialists Meeting
July 7, 2022 | finanznachrichten.de
Iveric Bio and DelSiTech: DelSiTech and Iveric Bio Enter Exclusive Agreement for Development of Sustained Release Zimura
July 7, 2022 | markets.businessinsider.com
Expert Ratings for IVERIC bio
See More Headlines
Receive ISEE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IVERIC bio and its competitors with MarketBeat's FREE daily newsletter.

ISEE Company Calendar

Last Earnings
7/26/2022
Today
10/05/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ISEE
CUSIP
N/A
CIK
1410939
Web
ivericbio.com
Phone
(212) 845-8200
Fax
N/A
Employees
94
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$26.00
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+25.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.22)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-114,520,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-46.62%
Return on Assets
-43.18%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.98
Quick Ratio
11.98

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.14 per share
Price / Book
6.62

Miscellaneous

Outstanding Shares
118,080,000
Free Float
114,890,000
Market Cap
$2.46 billion
Optionable
Optionable
Beta
0.98

Key Executives

  • Mr. Glenn P. Sblendorio M.B.A.Mr. Glenn P. Sblendorio M.B.A. (Age 66)
    CEO & Director
    Comp: $1.3M
  • Dr. Pravin U. Dugel M.D. (Age 58)
    Pres
    Comp: $926.9k
  • Mr. David F. Carroll M.B.A. (Age 56)
    Sr. VP, CFO & Treasurer
    Comp: $713.65k
  • Mr. Christopher Paul SimmsMr. Christopher Paul Simms (Age 47)
    Sr. VP & Chief Commercial Officer
    Comp: $668.25k
  • Mr. Anthony S. Gibney (Age 51)
    Exec. VP and Chief Bus. & Strategy Officer
    Comp: $1.5M
  • Dr. Samir C. Patel (Age 61)
    Co-Founder and Consultant
  • Mr. Keith Westby M.B.A.Mr. Keith Westby M.B.A. (Age 47)
    Sr. VP & COO
  • Dr. Xiao-Ping Dai Ph.D.
    Chief Technical Officer
  • Ms. Kathy Galante
    Sr. VP of Investor Relations & Corp. Communications
  • Mr. Todd D.C. Anderman
    Sr. VP, Gen. Counsel & Corp. Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













ISEE Stock - Frequently Asked Questions

Should I buy or sell IVERIC bio stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IVERIC bio in the last twelve months. There are currently 1 sell rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ISEE shares.
View ISEE analyst ratings or view top-rated stocks.

What is IVERIC bio's stock price forecast for 2022?

9 analysts have issued 1 year target prices for IVERIC bio's shares. Their ISEE share price forecasts range from $8.00 to $35.00. On average, they predict the company's stock price to reach $26.00 in the next twelve months. This suggests a possible upside of 24.4% from the stock's current price.
View analysts price targets for ISEE or view top-rated stocks among Wall Street analysts.

How have ISEE shares performed in 2022?

IVERIC bio's stock was trading at $16.72 on January 1st, 2022. Since then, ISEE shares have increased by 25.0% and is now trading at $20.90.
View the best growth stocks for 2022 here.

When is IVERIC bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our ISEE earnings forecast.

How were IVERIC bio's earnings last quarter?

IVERIC bio, Inc. (NASDAQ:ISEE) announced its quarterly earnings results on Tuesday, July, 26th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.10. During the same quarter in the prior year, the business posted ($0.32) earnings per share.

What is Glenn Spina's approval rating as IVERIC bio's CEO?

6 employees have rated IVERIC bio Chief Executive Officer Glenn Spina on Glassdoor.com. Glenn Spina has an approval rating of 41% among the company's employees. This puts Glenn Spina in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of IVERIC bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Maxar Technologies (MAXR), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Alibaba Group (BABA), Cisco Systems (CSCO) and Kinross Gold (KGC).

What is IVERIC bio's stock symbol?

IVERIC bio trades on the NASDAQ under the ticker symbol "ISEE."

How do I buy shares of IVERIC bio?

Shares of ISEE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IVERIC bio's stock price today?

One share of ISEE stock can currently be purchased for approximately $20.90.

How much money does IVERIC bio make?

IVERIC bio (NASDAQ:ISEE) has a market capitalization of $2.47 billion. The company earns $-114,520,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis.

How can I contact IVERIC bio?

IVERIC bio's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The official website for the company is ivericbio.com. The company can be reached via phone at (212) 845-8200 or via email at kathy.galante@ivericbio.com.

This page (NASDAQ:ISEE) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.